

Supplementary Table 1. Factors associated with death in PD and HD patients with COVID-19 infection

Characteristic	HD group		PD group	
	Adjusted OR ^b (95% CI)	p-value	Adjusted OR ^b (95% CI)	p-value
Age	1.04 (1.03–1.05)	<0.001	1.03 (1.02–1.04)	<0.001
Male ^a	1		1	
Female	0.91 (0.72–1.16)	0.40	0.78 (0.60–1.03)	0.08
Diabetes	1.00 (0.76–1.31)	0.90	1.68 (1.22–2.33)	0.02
Cardiovascular disease	1.75 (1.37–2.23)	<0.001	1.08 (0.82–1.43)	0.60
Cerebrovascular disease	1.14 (0.82–1.57)	0.40	1.17 (0.81–1.67)	0.40
Malignancy	1.04 (0.59–1.75)	0.90	0.67 (0.25–1.52)	0.40
Hypertension	1.16 (0.63–2.30)	0.60	0.41 (0.18–1.03)	0.40
Airway disease	0.76 (0.50–1.13)	0.20	0.79 (0.49–1.23)	0.30
Liver disease	0.81 (0.59–1.11)	0.20	1.21 (0.83–1.73)	0.30
Psychiatric problem	1.51 (0.98–2.27)	0.05	0.73 (0.39–1.31)	0.30
Number of vaccination doses				
No vaccination	1		1	
Single dose ^a	0.88 (0.68–1.13)	0.30	0.46 (0.31–0.66)	<0.001
Double dose	0.32 (0.21–0.49)	<0.001	0.24 (0.12–0.42)	<0.001
At least three doses	0.58 (0.03–3.48)	0.60	NA	NA
Type of vaccine without mRNA ^a	1		1	
With mRNA	1.23 (0.39–5.46)	0.80	1.45 (0.41–9.29)	0.60

CI, confidence interval; COVID 19, coronavirus disease 2019; HD, hemodialysis; mRNA, messenger RNA; NA, not available; OR, odds ratio; PD, peritoneal dialysis.

^aReference to calculate ORs. ^bAdjusted for age, sex, diabetes, cardiovascular disease, cerebrovascular disease, malignancy, hypertension, airway disease, liver disease, psychiatric problems, the number of doses in vaccination, and types of vaccine.